Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AbbVie has multiple products approved and marketed globally, with extensive revenue from immunological, oncological, neuroscientific, and virology indications. Its lead drug, adalimumab (Humira), was a top-selling pharmaceutical for years. The company is advancing broad late-stage and early-stage clinical programs, including recent expansion into oncology (notably ovarian cancer via ImmunoGen deal), neuroscience, and molecular glue therapy with robust clinical results across these areas.[1][2]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Various pharmaceutical companies including AbbVie.